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Abstract
Background: Osteopontin (OPN) is a secreted phosphoprotein often overexpressed at high levels in the blood and
primary tumors of breast cancer patients. OPN contains two integrin-binding sites and a thrombin cleavage
domain located in close proximity to each other.
Methods: To study the role of the thrombin cleavage site of OPN, MDA-MB-468 human breast cancer cells
were stably transfected with either wildtype OPN (468-OPN), mutant OPN lacking the thrombin cleavage domain
(468-ΔTC) or an empty vector (468-CON) and assessed for in vitro and in vivo functional differences in malignant/
metastatic behavior.
Results: All three cell lines were found to equivalently express thrombin, tissue factor, CD44, avb5 integrin and b1
integrin. Relative to 468-OPN and 468-CON cells, 468-ΔTC cells expressing OPN with a deleted thrombin cleavage
domain demonstrated decreased cell adhesion (p < 0.001), decreased mRNA expression of MCAM, maspin and
TRAIL (p < 0.01), and increased uPA expression and activity (p < 0.01) in vitro. Furthermore, injection of 468-ΔTC
cells into the mammary fat pad of nude mice resulted in decreased primary tumor latency time (p < 0.01) and
increased primary tumor growth and lymph node metastatic burden (p < 0.001) compared to 468-OPN and
468-CON cells.
Conclusions: The results presented here suggest that expression of thrombin-uncleavable OPN imparts an early
tumor formation advantage as well as a metastatic advantage for breast cancer cells, possibly due to increased
proteolytic activity and decreased adhesion and apoptosis. Clarification of the mechanisms responsible for these
observations and the translation of this knowledge into the clinic could ultimately provide new therapeutic
opportunities for combating breast cancer.
Background
Breast cancer is a leading cause of cancer death in
women, mainly due to metastasis of the disease to dis-
tant organs. How the process of metastasis occurs, and
what biological factors may contribute to it, is an impor-
tant field of research being undertaken. It is believed
that with improved understanding of the biology of the
disease we can develop new diagnostic, prognostic and
therapeutic methods. The current study is focused on
examining the interaction of two such factors; thrombin
and osteopontin (OPN).
OPN has been clinically associated with many types of
human cancer [1-10]. Specifically in breast cancer
patients with metastatic disease, elevated levels of base-
line OPN in plasma have been linked to poor prognosis
[11,12]. Other studies have found that changes in OPN
plasma level over time after therapy are associated with
clinical outcome [13]. Experimentally, OPN has been
functionally associated with growth, survival, adhesion,
migration, invasion, angiogenesis and metastasis of
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shown to interact with cell surface receptors (integrins,
CD44) [15,19,21,25], secreted proteases (urokinase plas-
minogen activator, thrombin) [17,24] and growth factor/
receptor pathways (EGFR, Met) [16,18] in order to exert
its malignancy-promoting effects.
OPN has many protein interaction domains which are
thought to play a role in the function of the protein.
These include two integrin binding sites (RGD [argi-
nine
159- aspartic acid
161] and SVVYLR [serine
162-
arginine
168]; a CD44 binding domain; and a thrombin
cleavage domain (RSK [arginine
168-lysine
170]) [26].
When OPN is cleaved at the RSK site by thrombin, it is
separated into two approximately equivalent sized
pieces, including N-terminal and C-terminal fragments
[27]. Thrombin itself is a secreted serine protease found
in the blood and an integral protein in the processes of
haemostasis and coagulation [28]. Thrombin is activated
upstream by tissue factor (TF) which is exposed on the
surface of endothelial cells after injury, but is also often
overexpressed on the surface of cancer cells [29]. The
tumor microenvironment thus provides a rich environ-
ment for abundant activation of thrombin and therefore
OPN cleavage.
The effect of OPN cleavage by thrombin has
been previously studied by ourselves and others
[24,27,30,31]. Senger et al. [27], demonstrated that
when OPN is cleaved by thrombin, in vitro adhesion
and migration of cancer cells is increased, specifically
due to the N-terminal domain of OPN, possibly by
increasing access to the integrin binding domains
[27,30]. However, work by Mi et al. [31] observed that
it is the C-terminal domain of thrombin-cleaved OPN
that increases both migration and adhesion of breast
cancer cells. This C-terminal effect occurs by complex-
ing with cyclophilin C and binding of CD147 on the
cell surface [31]. Our laboratory has previously shown
that blockage of thrombin activity using Argatroban (a
clinically used thrombin inhibitor) specifically reduced
adhesion and migration of MDA-MB-468 breast cancer
cells transfected with OPN (468-OPN) but had no
effect on control cells (468-CON) [24]. Furthermore,
Argatroban treatment of tumor-bearing mice reduced
primary tumor growth, lymphovascular invasion, and
lymph node metastasis using both OPN-dependent and
OPN-independent mechanisms [24]. This data from
our lab clearly shows that pharmacologic inhibition of
thrombin activity can reduce OPN-mediated metastatic
behavior. However, the specific biochemical interaction
between thrombin and osteopontin and its role in
mediating breast cancer cell malignancy requires
further elucidation.
In the current study, we investigated the biochemical
and functional relationship between OPN and thrombin
during breast cancer metastasis using the 468-CON and
468-OPN human breast cancer cell lines, as well as a
third cell line (468-ΔTC) which expresses a mutant
OPN lacking the thrombin cleavage domain. In doing
this, we hoped to identify those effects of OPN that
were due to its direct thrombin cleavage rather than
effects simply related to pharmacological inhibition of
host- and/or tumor cell-produced thrombin. We
hypothesized that deletion of the thrombin cleavage site
on the OPN protein backbone would alter the ability of
OPN to mediate breast cancer malignancy and metasta-
sis. Unexpectedly, the novel findings presented here
indicate that breast cancer cells expressing thrombin-
uncleavable OPN demonstrate enhanced metastatic
behavior in vitro and in vivo relative to cells expressing
wildtype OPN.
Methods
Cell Culture
The tumorigenic, weakly metastatic MDA-MB-468
human breast cancer cell line (a kind gift from Dr. Janet
Price, University of Texas, M.D. Anderson Cancer Cen-
ter, Houston, TX) was maintained in aMEM medium
(Invitrogen; Carlsbad, CA) supplemented with 10% fetal
bovine serum (FBS, Sigma Chemical Company;
St. Louis, MO) at 37°C in a humidified CO2 incubator.
Plasmids & Transfection
Stable transfection of MDA-MB-468 human breast can-
cer cells was carried out using liposome-based transfec-
tion as described previously ([21]. Plasmids for
transfections included an unmodified pcDNA3 control
plasmid (Invitrogen); a wildtype OPN expression vector
that was previously generated by cloning the full-length
human OPN cDNA (from plasmid OP-10) into
pcDNA3 [32,33]; and a mutant OPN expression vector
in which the thrombin cleavage region (
166GLRSKS
171)
was deleted. The thrombin-uncleavable OPN expression
construct was generated by site-directed mutagenesis of
the wildtype OPN expression plasmid using a 49 mer
mutagenic oligonucleotide specific for introducing the
thrombin cleavage deletion (ΔTC) (5’ GGATGT-
CAGGTCTGCGAAACTTCTTATAAACCACACTAT-
CACCT CGGCC 3’). In order to control for clonal
heterogeneity, pooled populations were created by com-
bining several clonal cell populations that resulted from
the stable transfections. The specific cell populations
generated included a control vector-transfected
MDA-MB-468 pooled population consisting of 6 clones
(468-CON), an OPN-transfected MDA-MB-468 pooled
population consisting of 6 clones (468-OPN) [21] and a
ΔTC-OPN-transfected MDA-MB-468 pooled population
consisting of 6 clones (468-ΔTC). To maintain stable
transgene expression, cell lines were maintained under
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(G418-sulfate, Invitrogen).
Western Blot Analysis
Cells were plated at 10
6 cells/100 mm plate, grown for
48 hrs and media was changed to Opti-MEM media
(Invitrogen). Conditioned media was collected after 18
hrs and cells were counted. For each cell line, a normal-
ized volume of conditioned media equivalent to 5 × 10
5
cells was subjected to electrophoresis in 10% SDS-
polyacrylamide gels and transferred onto polyvinylidene
difluoride membranes (Immobilon™, Millipore; Bedford,
MA). After transfer, gels were stained with Coomassie
Blue to confirm equal loading and transfer efficiency.
Primary antibodies included a sheep polyclonal anti-
human antibody against tissue factor (TF, Cedarlane
Laboratories; Burlington, ON, 1:2000 dilution), a mouse
monoclonal anti-human antibody against thrombin
(clone 12, BD Biosciences; Franklin Lakes, NJ, 1:1000
dilution), and a rabbit monospecific polyclonal anti-
human antibody against OPN (hOPN1; 7.5 μg/ml), a
k i n dg i f tf r o mD r .T o s h iU e d e ,H o k k a i d oU n i v e r s i t y ,
Sapporo, Japan [34]. The secondary antibodies used
were anti-sheep (TF), anti-mouse (thrombin) (Sigma)
or anti-rabbit (OPN) (GE Healthcare, Little Chalfont
Buckinghamshire, UK) HRP conjugates (1:2000 dilution).
The blocking/dilution reagent used was 5% skim milk in
TBST (Tris-buffered saline + 0.05% Tween-20). Throm-
bin, TF, and OPN protein expression was visualized
using an enhanced chemiluminescence system (Roche
Applied Sciences; Laval, QC).
Flow Cytometry Analysis
Cells were grown to ~80% confluence in normal media
and harvested by gentle trypsinization. Flow cytometry
analysis of cell surface receptors was carried out using
the appropriate primary antibodies against integrins: b1,
b3, avb5, a9b1, (Chemicon) or IgG (negative isotype con-
trol) (1 μg/10
6 cells) (Cedarlane, Mississauga, ON) for
1 hr at 4°C and phycoerytherin (PE)-labeled secondary
antibody (BD Biosciences, Franklin Lakes, NJ) for 1 hr
i nt h ed a r k .S a m p l e sw e r er u no naB e c k m a nC o u l t e r
EPICS XL-MCL flow cytometer. For CD44 expression
analysis, CD44-PE and IgG-PE (negative isotype control)
(BD Biosciences) antibodies were used and analyzed in a
similar fashion.
Cell Adhesion Assay
Cells were plated onto sterile 96-well non-tissue culture
plates (Titertek, Flow Laboratories Inc.; McLean, VA)
coated with either 5 μg/ml of human vitronectin (VN;
Sigma) or PBS (negative control), using 1 × 10
4 cells/
well in triplicate wells for each treatment. The experi-
ment was completed three times. Vitronectin was
chosen because it is a ligand for avb1a n davb5, two
integrins that are known to interact with OPN (via the
RGD region), and that are expressed by MDA-MB-468
cells. For each cell line, experiments were conducted in
t h ep r e s e n c eo ra b s e n c eo f2 5μg/ml Argatroban (pre-
treatment period of 15 min) or 25 μg/ml integrin block-
ing antibodies (avb5 or b1) (Chemicon, Temecula, CA).
Cells were allowed to adhere for 5 h at 37°C. Adhered
cells were then fixed using fresh 2% gluteraldehyde/PBS
and stained using Harris’ hematoxylin. Blue stained cells
were manually counted using a light microscope. Five
high-powered fields (HPF) of view were counted for
each well, and the mean number of cells per HPF were
calculated and compared. Argatroban (Abbott Labora-
tories; North Chicago, IL) was purchased through the
London Health Science Centre pharmacy.
Cell Growth Assays
Cells were plated at a density of 5.0 × 10
4 cells/60 mm
plate (n = 3 for each time point) and maintained in reg-
ular growth media. Every 48 h for 12 days, triplicate cul-
tures were trypsinized and manually counted for viable
cells using a hemocytometer and trypan blue exclusion.
Cell Migration Assays
In preparation for the assay, 6.5 mm Transwell plates
with a 8.0 μm pore size (Becton Dickinson; Franklin
Lakes, NJ) were pre-coated with gelatin (6 μg/well, n = 3
wells per experimental group). Media containing a che-
moattractant (10% FBS) or serum-free media + 0.1% BSA
(negative control) was added to the bottom chamber of
the Transwell plates. Cell suspensions (5.0 × 10
4 cells/
well in serum-free growth medium + 0.1% BSA) were
added to the top of the wells and allowed to incubate at
37°C for 24 h. The upper portion of the transwell was
removed, inverted, and fixed using fresh 1% gluteralde-
hyde/PBS and stained using Harris’ hematoxylin. Wells
were rinsed with distilled water and any non-migrated
cells were carefully removed with a cotton swab. Five
HPF of view were manually counted for each well, and
the mean number of cells per HPF was calculated and
compared.
Semi-Quantitative Zymography
Conditioned media were prepared as described in the
western blot methodology. For each cell line, a normal-
ized volume of conditioned media equivalent to 5 × 10
3
cells was subjected to electrophoresis in 10% SDS-polya-
crylamide gels supplemented with 2 mg/ml of casein
and 5 μg/ml of plasminogen (Sigma). Gels were washed
twice for 15 min each in 2.5% Triton X-100 solution to
remove SDS followed by 5 washes in water. Enzymatic
activity was measured after 18 hr of incubation at 37°C
in incubation buffer (50 mM Tris-HCl and 5 mM
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Coomassie Blue for 1 hour and destained. White bands
representing enzymatic activity were measured by densi-
tometric analysis using a BioRad Universal Hood II and
Quantity One 4.6.1 software (BioRad). Density measure-
ments were normalized to 468-CON samples for each
biological replicate and pooled for analysis.
In Vivo Tumorigenicity and Metastasis Assays
Animal research conformed to the Helsinki Declaration
and to local legislation. All animal procedures were con-
ducted in accordance with the recommendations of the
Canadian Council on Animal Care, under a protocol
approved by the University of Western Ontario Council
on Animal Care.
Cells were prepared in sterile PBS at a concentration
of 1 × 10
6 cells/100 μl and injected into the second
thoracic mammary fat pad of 7-8 week-old female athy-
m i cn u d e( nu/nu) mice as described elsewhere, using
1×1 0
6 cells/mouse and 12 mice/treatment group [21].
Primary tumor growth was evaluated weekly by caliper
measurement in two perpendicular dimensions, and
tumor volume was estimated using the following for-
mula: [volume = 0.52 × (width)
2 × (length)] for approxi-
mating the volume (mm
3) of an ellipsoid. Differences in
mean tumor volume were analyzed for each weekly time
point.
As per previously established endpoints [21], mice
were sacrificed at approximately 12 weeks post-injection
and assessed for metastatic burden. Tissues and organs
were examined superficially for evidence of gross macro-
scopic metastases at necropsy, prior to processing for
histology. Primary tumors and mouse tissues collected
at necropsy were fixed in 10% neutral-buffered formalin
before processing. Tissues were embedded in paraffin
wax, sectioned (4 μm thick), and subjected to standard
hematoxylin and eosin (H&E) staining. Stained slides
were evaluated by light microscopy in a blinded fashion
by an experienced pathologist in order to observe histo-
pathological characteristics and to identify regions of
micrometastatic involvement. Color RGB (Red Green
Blue) images were taken using an Olympus
© microscope
(Olympus America, Center Valley, PA) and regions of
micrometastatic involvement were manually outlined.
Metastatic tumor burden in the lymph node (tumor
area/organ total area) was determined quantitatively
using ImageJ analysis software (NIH). Color images
were converted to 8-bit images and thresholding was
performed on each picture to obtain a black (manually
outlined total organ tissue or total tumor tissue) and
white (background) image. Quantification was done
using the ‘analyze particles’ option of the ImageJ soft-
ware after the scale had been set for the microscope
objective used.
RNA Extraction and Quantitative Real-Time PCR
Cells were grown on 60 mm diameter dishes until ~80%
confluence (3 dishes/cell line) and total RNA was col-
lected using the TRIzol
® Reagent (Invitrogen) system as
per the manufacturer’s protocol. Total RNA was quanti-
fied by spectrophotometry, assuming an absorbance
(at 260 nm) of 1.0 equal to 40 μg RNA/mL. cDNA was
created from 1 μg of total RNA using SuperScript III
Reverse transcriptase, oligo(dt)20 primers, 10 mM dNTP
Mix, 5× Strand Buffer, 0.1 M DTT and RNase out (Invi-
trogen). Reverse transcription (no SuperScript III) were
run with every reaction group.
Real-time PCR was conducted with a Rotor-Gene 3000
temperature cycler (Corbett Research, San Francisco, CA)
using cDNA as a template and Brilliant
® SYBR
® Green
QPCR Master Mix (Stratagene), following the manufac-
turer’s protocol. Expression was normalized to glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) internal
control and further compared to the 468-CON cell line.
Reverse transcription (no SuperScript III) and non tem-
plate (no cDNA) controls were run with every reaction to
ensure that genomic DNA was not amplified and the
reagents were not contaminated. Primers used: GAPDH
[Forward 5’-CATGTTCGT CATGGGTGTGAACCA-3’,
Reverse 5’-ATGGCATGGACTGTGGTCATGAGT-3’];
uPA [Forward 5’-CAGGGCATCTCCTGTGCATG-3’,
Reverse 5’-AGCCCTG CCCTGAAGTCGTTA-3’];
MCAM [Forward 5’-GGGTACCCCATTCCTCAAGT-3’,
Reverse 5’-CCTGGACTCCTTCATGTGGT-3’]; Maspin
(SERPINB5) [Forward 5’-CTACTTTGTTGGCAAGTGG
ATGAA-3’, Reverse ACTGGTTTGGTGTCTGTC TT
GTTG-3’]; and TRAIL (TNFSF10) [Forward 5’-CGT
GTACTTTACCAACGAG CTGA-3’,R e v e r s e5 ’-ACG-
GAGTTGCCACTTGACTTG-3’].
Statistical Analysis
All in vitro experiments were performed at least in tri-
plicate, and data were compiled from 3 separate experi-
ments. In vivo studies were carried out using multiple
animals (n = 12 per experimental group). Statistical ana-
lysis was performed using GraphPad Prism 4.0 software
©
(San Diego, CA) using ANOVA with Tukey post hoc
test (for comparison between more than two groups).
Growth curve analysis was done using Prism 4.0, using
non-linear regression with an F-test. In all cases, values
of p ≤ 0.05 were regarded as being statistically
significant.
Results
Characterization of OPN, thrombin, TF, and OPN-related
receptor expression in transfected MDA-MB-468 cells
MDA-MB-468 breast cancer cells were stably trans-
fected to overexpress either wildtype OPN (468-OPN),
thrombin-uncleavable OPN (468-ΔTC) or an empty
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characterized for their expression of the secreted pro-
teins OPN, thrombin, and TF using western blot analy-
sis (Figure 1A) and for the OPN-related receptors b1
integrin, b3 integrin, avb5i n t e g r i n ,a9b1i n t e g r i na n d
CD44 using flow cytometry analysis (Figure 1B).
All three cell lines strongly expressed both thrombin
and TF at approximately equivalent levels, indicating
that they would be present in the in vitro tissue culture
environment during experimental assays (Figure 1A).
Relative to 468-CON cells, 468-OPN and 468-ΔTC cells
expressed high levels of OPN protein (Figure 1A). How-
ever, only the 468-OPN cells expressed the N-terminal
cleavage product of OPN, indicating that the thrombin
expressed by the cells is capable of cleaving only the
wildtype OPN produced by 468-OPN cells and not the
thrombin uncleavable OPN produced by 468-ΔTC cells.
In addition, the OPN expressed by the 468-ΔTC cells
ran slightly smaller than the wildtype indicating its
smaller size due to the deleted region (Figure 1A). Inter-
estingly, we observed an additional ~55 kDa band
expressed by 468-ΔTC cells, which may represent a
novel post-translational modification.
It was also found that each cell line equivalently
expressed CD44, avb5i n t e g r i na n db1 integrin, but not
b3o ra9b1 integrins. (Figure 1B). Representative results
for 468-CON cells only are shown; however equivalent
expression was observed in all cell lines (Additional File 1,
Figure S1). Therefore any differences seen between the
cell lines in subsequent experimental assays would not be
due to variable receptor expression.
Deletion of the thrombin-cleavage region of OPN reduces
in vitro cell adhesion of MDA-MB-468 cells
In vitro assays were carried out to measure adhesion of
the cell lines to vitronectin (VN), a ligand for avb5a n d
avb1 integrins expressed by the MDA-MB-468 cells.
Treatments consisted of Argatroban (thrombin inhibitor,
25 μg/ml), b1o ravb5 integrin blocking antibodies, or
IgG (negative control) (25 μg/ml). Interestingly, the 468-
OPN cells exhibited significantly increased adhesion
compared to 468-CON and 468-ΔTC cells (p < 0.001),
whereas the 468-ΔTC cells demonstrated significantly
decreased adhesion compared to both 468-CON and
468-OPN cells (p < 0.001) (Figure 2). The increased
adhesion in 468-OPN cells was dependant on thrombin
cleavage as evidenced by the significant decrease of
these behaviors when treated with the thrombin inhibi-
tor Argatroban (p < 0.05). Treatment with b1o ravb5
blocking antibodies also significantly decreased adhesion
of 468-OPN cells (p < 0.05), whereas the IgG isotype
control antibody had no effect. Argatroban and integrin
blocking antibodies had no effect on 468-ΔTC cell
adhesion.
No difference was observed between 468-CON,
468-OPN, and 468-ΔTC cell lines with regards to cell
proliferation in vitro (Additional File 2, Figure S2A).
Although we did observe that both 468-OPN and
468-ΔTC were significantly more migratory relative to
468-CON cells, there was no significant difference in
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Figure 1 In vitro protein expression of OPN, thrombin, TF, and
OPN-related receptors in 468-CON, 468-OPN and 468-ΔTC cells.
(A) Protein expression of OPN, thrombin, and tissue factor (TF) was
analyzed by western blot analysis of conditioned media from 5 ×
10
5 cultured cells for each cell line as described in the Materials and
Methods. (B) Receptor expression was measured by flow cytometry
analysis. Cultured cells were incubated with specific antibodies (filled
profiles) or with a nonspecific isotype control primary antibody
(open profiles). Filled profiles represent expression of a9b1 integrin,
b1 integrin, b3 integrin, avb5 integrin and CD44. Representative
results for 468-CON cells only are shown; equivalent expression was
observed in all cell lines (data not shown).
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tional File 2 ,F i g u r eS 2 B ) .T h i sd a t ai sc o n s i s t e n tw i t h
our previous studies using the 468-CON and 468-OPN
cell lines [21,24].
Deletion of the thrombin-cleavage region of OPN
enhances in vitro proteolytic activity of MDA-MB-468 cells
To determine any proteolytic differences between the
transfected cell lines, urokinase plasminogen activator
(uPA) expression and activity were measured using
quantitative real-time PCR and semi-quantitative zymo-
graphy with subsequent densitometric analysis. The
468-ΔTC cells displayed significantly increased uPA
expression (Figure 3A) and activity (Figure 3B,C) relative
to both the 468-CON (p < 0.01) and 468-OPN (p <
0.001) cells. No differences in uPA expression or activity
were observed between the 468-CON and 468-OPN
cells.
Deletion of the thrombin-cleavage region of OPN
decreases tumor latency, increase primary tumor growth,
and enhances lymph node metastasis of MDA-MB-468
cells in vivo
To assess how OPN and thrombin-uncleavable OPN affect
initiation and growth of primary tumors and metastases,
an in vivo mouse model consisting of athymic nude (nu/
nu) mice was used. Twelve mice per transfected cell line
were injected with 1 × 10
6 cells into the mammary fat pad
and tumor volume was measured weekly. With the excep-
tion of one mouse in the 468-CON group, all mice devel-
oped tumors. Initially, mice injected with both 468-OPN
(p < 0.05) and 468-ΔTC (p < 0.001) cells grew significantly
larger tumors than mice injected with 468-CON cells (Fig-
ure 4A). However, after day 42 the significant difference in
tumor size between the 468-OPN and 468-CON groups
was lost. At day 42, the 468-ΔTC group began growing
tumors significantly larger than the 468-OPN and 468-
CON groups (p < 0.05) (Figure 4A). The final mean tumor
volume of the 468-ΔTC group was 2255.4 +/- 231.1 mm
3;
significantly larger than the 468-CON group, whose final
mean tumor volume was 1066.2 mm
3 +/- 209.5 (p < 0.01).
Interestingly, the mean tumor latency time (time to
reach 500 mm
3) was significantly shorter for the 468-
ΔTC group compared to both the 468-CON (p < 0.01)
and 468-OPN groups (p < 0.05) (Figure 4B). However,
the rate of tumor growth (i.e. doubling time) for each
group was not observed to be significantly different
when analyzed using non-linear regression analysis
(data not shown).
At twelve weeks post-injection mice were sacrificed
and assessed for metastatic characteristics. Tissue sec-
tions from lymph nodes (LN) were subjected to H&E
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Figure 2 In vitro cell adhesion of 468-CON, 468-OPN and 468-ΔTC cells. 96 well plates were pre-coated with vitronectin (5 μg/ml) or PBS
(neg. control). 1 × 10
4 cells/well and 3 wells/treatment were plated and allowed to adhere for 5 hrs. Experiments were carried out in the
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blinded fashion. The severity of metastasis in those
lymph nodes which had been deemed positive for tumor
cells was determined by measuring tumor burden.
Specifically, mean LN metastatic burden (% of LN occu-
pied by tumor) was calculated and showed a signifi-
cantly higher burden in mice injected with 468-ΔTC
cells than those injected with either 468-CON or 468-
OPN cells (p < 0.001) (Figure 4C).
Differential expression of MCAM, Maspin and TRAIL is
consistent with the functional differences observed
between 468-CON, 468-OPN, and 468-ΔTC cells
Finally, to identify genes potentially involved in the
functional differences observed between the transfected
cell lines, a preliminary gene expression analysis was
undertaken using a Human Genome U133 Plus 2.0
Array (data not shown). Analysis is ongoing, however
several potential genes were identified that may play a
mechanistic role in the effects observed in 468-ΔTC
cells and were subsequently validated using quantitative
real-time PCR (Figure 5). Expression of the adhesion
molecule MCAM was found to be significantly
decreased in 468-ΔTC cells compared to 468-OPN cells
(p < 0.01) (Figure 5A). This is consistent with the func-
tional effects observed, whereby 468-ΔTC cells showed
significantly less cell adhesion than 468-OPN cells (Fig-
ure 2). The same was true of the uPA inhibitor maspin
(SERPINB5), which was significantly decreased in
468-ΔTC cells compared to 468-OPN cells (p < 0.001)
(Figure 5B). Again, this is consistent with the increased
uPA expression and proteolytic activity in the 468-ΔTC
cells observed in vitro (Figure 3) and the increased
metastasis observed in vivo (Figure 4C). Lastly, the pro-
apoptotic protein TNF-related apoptosis inducing ligand
(TRAIL) which is encoded by the gene TNFSF10 was
significantly reduced in 468-ΔTC compared to control
(p < 0.01) (Figure 5C), consistent with the decreased
tumor latency and increased tumor size observed in the
in vivo studies (Figure 4A,B).
Discussion
The secreted phosphoprotein OPN has been shown to
be both prognostically and functionally important for
breast cancer progression and metastasis [11-24]. How-
ever, the mechanistic ways in which OPN exerts these
effects on breast cancer cells is still not well understood.
Previous studies from our lab using the direct thrombin
inhibitor Argatroban suggested that thrombin activity
and subsequent cleavage of OPN is important for OPN
to promote cancer progression and metastasis [24].
These results were focused more on globally knocking
down host and/or tumor cells thrombin activity and
indirectly observing the effect on OPN cleavage. In con-
trast, the current study focused specifically on OPN
cleavage by comparing stably transfected cell lines
expressing either wildtype OPN or a mutant OPN lack-
ing the thrombin cleavage domain. Our novel findings
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Page 8 of 12indicate that loss of the thrombin cleavage domain actu-
ally promotes breast cancer cell progression and metas-
tasis both in vitro and in vivo to a level exceeding that
of wildtype OPN.
Using the stably transfected cell lines 468-OPN, 468-
ΔTC and 468-CON, we investigated how thrombin
cleavage of OPN impacts breast cancer cell function
using in vitro and in vivo experiments representative of
behaviors important to breast cancer progression and
metastasis. Each cell line was characterized for expres-
sion of various OPN-related proteins. All three cell lines
equivalently expressed thrombin, TF, CD44, avb5a n d
b1 integrins, therefore ensuring any differences in beha-
vior observed were due to differences in OPN and not
to differences in OPN-related proteins. It was also con-
firmed that the 468-OPN cell line expressed both full
length and cleaved OPN, whereas the 468-ΔTC cells
express only the full length protein. Interestingly, we
observed an additional ~55 kDa band expressed by 468-
ΔTC cells. Due to post-translational modifications such
as glycosylation/sialation and phosphorylation, the mole-
cular weight of OPN in monomeric form varies widely
(41-75 kDa) [22]. However, the numerous forms of
post-translationally modified OPN are very poorly
understood, particularly with regards to their differential
functional effects on cell behavior. It is possible that the
additional ~55 kDa band expressed by 468-ΔTC cells
represents a novel post-translational modification, and
that this is related to the observed downstream func-
tional effects.
In vitro analysis comparing the adhesive capabilities of
the cells indicated that wildtype OPN increases adhesion
of breast cancer cells whereas ΔTC-OPN decreases
adhesion. The increased adhesion caused by wildtype
OPN was specific to thrombin activity and integrin
binding. This is in keeping with previous studies show-
ing that pre-cleaved N-terminal OPN (containing the
integrin binding sites) demonstrates increased adhesion
over full-length wildtype OPN [24,27,30]. In contrast,
the 468-ΔTC cells had decreased adhesive capabilities
independent of thrombin or integrin blocking. Interest-
ingly, the expression of the adhesion molecule MCAM
by 468-ΔTC cells was also decreased significantly com-
pared to 468-OPN cells. Loss of MCAM expression has
been hypothesized to increase detachment of cells and
therefore increase metastatic ability [35].
Urokinase plasminogen activator (uPA) is an impor-
tant mediator of matrix degradation and invasiveness
of cancer cells [36]. Both expression and activity of
uPA was significantly elevated in 468-ΔTC cells. Also,
expression of the uPA inhibitor and tumor suppressor
maspin [37] was significantly higher in 468-OPN cells
compared to 468-ΔTC cells, consistent with the
increased uPA expression and proteolytic activity in
468-ΔTC cells observed in vitro and the increased
metastasis observed in vivo. This suggests that ΔTC-
OPN is capable of modulating several components of
the uPA system. Wildtype OPN has previously been
shown to increase uPA activity; however those studies
used shorter treatments of exogenous OPN from
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Figure 5 mRNA expression of MCAM, Maspin and TRAIL in
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[17,32,38,39] rather than endogenously expressed OPN.
There is still uncertainty in the literature concerning
the post-translational modifications of OPN, and speci-
fically the differences in host versus tumor derived
OPN [40], which may also account for differences in
observed results.
Although in vitro functional assays help us to describe
individual behaviors of cancer cells, the human body is a
complex system. We therefore also compared the cell
lines using in vivo mammary fat pad injections and spon-
taneous metastasis assays in nude mice. Previous studies
have demonstrated that there is a role for OPN in in vivo
primary tumor growth of multiple cancer types [41-46].
Specifically in breast cancer, there are numerous reports
of OPN knockdown that lead to decreased in vivo tumor
growth [47-49]. Previous studies from our group and
others aimed at blocking OPN cleavage in vivo by phar-
macologically inhibiting thrombin indicate that inhibition
of thrombin can reduce malignant and metastatic beha-
vior of breast cancer cells using both OPN-dependent
and OPN-independent mechanisms [24,50]. The current
study found that directly removing the thrombin cleavage
domain from OPN produced significantly larger tumors
in a shorter time span than wildtype OPN or control.
Also, the growth rates (i.e. doubling time) were not sig-
nificantly different, indicating that thrombin-uncleavable
OPN may grant breast cancer cells an early advantage in
tumor initiation. The cause of this early advantage could
be linked to decreased apoptosis of the cells through
decreased expression of the pro-apoptotic ligand TRAIL
[51,52]. Mice injected with 468-ΔTC cells were also
found to have increased metastatic burden to the lymph
nodes indicating increased severity of metastasis. The
increased activity of the uPA system could help
the tumor metastasize more readily. In addition, the
decreased adhesion and expression of MCAM in 468-
ΔTC cells could also help to explain why there is an
increased effect on lymph node metastasis.
The bulk of evidence concerning OPN function impli-
cates the integrin binding domains in OPN-mediated
tumorigenesis [14-18,20-24]. However, some studies
show that it is the C-terminal half of OPN, containing
the CD44 binding domain, that is responsible for the
protein’s effects on cancer cells [31,53-55]. We hypothe-
size that deletion of the thrombin cleavage domain may
be interrupting integrin binding of OPN and therefore it
c o u l db eC D 4 4b i n d i n gt oO P Nw h i c hm a yb ec a u s i n g
the observed effects. Future studies to test this hypoth-
esis are currently being investigated.
Conclusions
In summary, the novel findings presented here demon-
strate that deletion of the thrombin cleavage domain
from OPN decreases in vitro cell adhesion and in vivo
primary tumor latency time, and increases in vitro uPA
expression and activity as well as in vivo primary tumor
growth and lymph node metastatic burden of MDA-
MB-468 breast cancer cells. To the best of our knowl-
edge, this is the first study to specifically study the
effects of OPN thrombin cleavage by site-directed muta-
genesis. Taken together, the results presented here sug-
gest that thrombin-uncleavable OPN conveys an early
tumor formation advantage as well as a metastatic
advantage, possibly due to increases in proteolytic activ-
ity and decreases in adhesion and apoptosis. Further
studies are needed to clarify whether ΔTC-OPN is sim-
ply refractory to cleavage, or whether the deletion
imparts some other additional effects such as altering
the conformation of OPN and/or inhibiting an unde-
fined interaction that in turn influence downstream
functional cell behavior. Elucidation of the mechanisms
responsible for these observations and the translation of
this knowledge into the clinic could ultimately provide
new therapeutic opportunities for combating breast
cancer.
Additional material
Additional file 1: Figure S1. Expression of various cell surface
integrin receptors and CD44 receptor in the 468-CON, 468-OPN,
and 468-ΔTC cell lines. Expression was measured by flow cytometry
analysis as described in the Materials and Methods. Cultured cells were
incubated with specific antibodies (filled profiles) or with a nonspecific
isotype control primary antibody (open profiles). Filled profiles represent
expression of a9b1 integrin, b1 integrin, b3 integrin, avb5 integrin and
CD44.
Additional file 2: Figure S2. In vitro cell proliferation and migration
of 468-CON, 468-OPN and 468-ΔTC cells. (A) Cell growth kinetics in
normal culture over time of 468-CON (black squares), 468-OPN (open
circles) and 468-ΔTC cells (open triangles) (n = 3 plates/timepoint). Data
are presented as the mean ± SEM. (B) Cell migration of 468-CON (black
bars), 468-OPN (white bars), and 468-ΔTC cells (hatched bars) towards
10% fetal bovine serum (FBS). Transwells (8 μm) were pre-coated with
gelatin (6 μg/well) and cells (5 × 10
4 cells/well; n = 3 for each treatment)
were allowed to migrate for 24 hrs. Migrated cells were quantified by
manual counting of 5 HPF per well. Data are presented as the mean ±
SEM. * = significantly different than 468-CON cells (p < 0.05). In all cases,
data are compiled from at least three separate experiments.
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